Esophageal Adenocarcinoma

Oncology·MeSH: Ovarian Neoplasms

17 drugs in development·9 companies·21 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
esoguard	Lucid Diagnostics Inc. (LUCD)

Phase 3(3)

Phase 2(7)

Drug	Company
Leucovorin	Jazz Pharmaceuticals plc (JAZZ)
Leucovorin	UNITED THERAPEUTICS Corp (UTHR)
Levoleucovorin Calcium	UNITED THERAPEUTICS Corp (UTHR)
mFOLFOX	Jazz Pharmaceuticals plc (JAZZ)
PF-08634404	Merus N.V. (MRUS)
Propranolol Hydrochloride	UNITED THERAPEUTICS Corp (UTHR)
Ramucirumab	Jazz Pharmaceuticals plc (JAZZ)

Preclinical(1)

Drug	Company
be-smart	ProPhase Labs, Inc. (PRPH)

Phase 1/Phase 2(1)

Drug	Company
Chemotherapy	Merus N.V. (MRUS)

Phase 2/Phase 3(2)

Drug	Company
CAPOX	BRISTOL MYERS SQUIBB CO (BMY)
FOLFOX	BRISTOL MYERS SQUIBB CO (BMY)

Phase 4(2)

Drug	Company
Ramucirumab	ENANTA PHARMACEUTICALS INC (ENTA)
tislelizumab	GH Research PLC (GHRS)

BioSniper tracks 17 drugs in development for Esophageal Adenocarcinoma across 9 companies.

There are 21 clinical trials targeting Esophageal Adenocarcinoma tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.